What mutational testing is considered the standard of care for NSCLC?
Should mutations other then EGFR and ALK be routinely tested for? Should next generation sequencing be routinely done?
1 Answer
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
The easy answer to this question is that the only molecular alterations for which we have matched FDA-approved drugs for those specific indications are EGFR and ALK, so the standard of care would be to test only for EGFR and ALK.
However, over the past 2-3 years, we came to appreciate that several o...
Join for free or sign in to see the full answer